Consensus 55c. Raises FY23 revenue view to $2.37B-$2.42B from $2.30B-$2.40B, consensus $2.37B. Raises FY23 adjusted EBITDA view to $540M-$550M from $525M-$540M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMRX:
- Amneal adds 2 denosumab biosimilars to U.S. pipeline oncology portfolio
- Amneal Pharmaceuticals management to meet with Trust
- Amneal Pharmaceuticals gets FDA approval for calcium gluconate injection
- Amneal receives ANDA approval from FDA for lisdexamfetamine dimesylate capsules
- Amneal Pharmaceuticals announces Sevelamer carbonate approval in China